Literature DB >> 20864632

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.

Camille Stephan-Otto Attolini1, Yu-Kang Cheng, Rameen Beroukhim, Gad Getz, Omar Abdel-Wahab, Ross L Levine, Ingo K Mellinghoff, Franziska Michor.   

Abstract

Human cancer is caused by the accumulation of genetic alterations in cells. Of special importance are changes that occur early during malignant transformation because they may result in oncogene addiction and represent promising targets for therapeutic intervention. Here we describe a computational approach, called Retracing the Evolutionary Steps in Cancer (RESIC), to deduce the temporal sequence of genetic events during tumorigenesis from cross-sectional genomic data of tumors at their fully transformed stage. When applied to a dataset of 70 advanced colorectal cancers, our algorithm accurately predicts the sequence of APC, KRAS, and TP53 mutations previously defined by analyzing tumors at different stages of colon cancer formation. We further validate the method with glioblastoma and leukemia sample data and then apply it to complex integrated genomics databases, finding that high-level EGFR amplification appears to be a late event in primary glioblastomas. RESIC represents the first evolutionary mathematical approach to identify the temporal sequence of mutations driving tumorigenesis and may be useful to guide the validation of candidate genes emerging from cancer genome surveys.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864632      PMCID: PMC2955151          DOI: 10.1073/pnas.1009117107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  Many faces of Ras activation.

Authors:  László Buday; Julian Downward
Journal:  Biochim Biophys Acta       Date:  2008-05-21

2.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

Authors:  Lauren T McGillicuddy; Jody A Fromm; Pablo E Hollstein; Sara Kubek; Rameen Beroukhim; Thomas De Raedt; Bryan W Johnson; Sybil M G Williams; Phioanh Nghiemphu; Linda M Liau; Tim F Cloughesy; Paul S Mischel; Annabel Parret; Jeanette Seiler; Gerd Moldenhauer; Klaus Scheffzek; Anat O Stemmer-Rachamimov; Charles L Sawyers; Cameron Brennan; Ludwine Messiaen; Ingo K Mellinghoff; Karen Cichowski
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

3.  Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Authors:  Rameen Beroukhim; Gad Getz; Leia Nghiemphu; Jordi Barretina; Teli Hsueh; David Linhart; Igor Vivanco; Jeffrey C Lee; Julie H Huang; Sethu Alexander; Jinyan Du; Tweeny Kau; Roman K Thomas; Kinjal Shah; Horacio Soto; Sven Perner; John Prensner; Ralph M Debiasi; Francesca Demichelis; Charlie Hatton; Mark A Rubin; Levi A Garraway; Stan F Nelson; Linda Liau; Paul S Mischel; Tim F Cloughesy; Matthew Meyerson; Todd A Golub; Eric S Lander; Ingo K Mellinghoff; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

4.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

Review 5.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Authors:  Ross L Levine; Animesh Pardanani; Ayalew Tefferi; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

6.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

7.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.

Authors:  Haihao Zhu; Jaime Acquaviva; Pranatartiharan Ramachandran; Abraham Boskovitz; Steve Woolfenden; Rolf Pfannl; Roderick T Bronson; John W Chen; Ralph Weissleder; David E Housman; Al Charest
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  Functional copy-number alterations in cancer.

Authors:  Barry S Taylor; Jordi Barretina; Nicholas D Socci; Penelope Decarolis; Marc Ladanyi; Matthew Meyerson; Samuel Singer; Chris Sander
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

View more
  68 in total

1.  Accurate reconstruction of the temporal order of mutations in neoplastic progression.

Authors:  Kathleen Sprouffske; John W Pepper; Carlo C Maley
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-13

2.  Algorithmic methods to infer the evolutionary trajectories in cancer progression.

Authors:  Giulio Caravagna; Alex Graudenzi; Daniele Ramazzotti; Rebeca Sanz-Pamplona; Luca De Sano; Giancarlo Mauri; Victor Moreno; Marco Antoniotti; Bud Mishra
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-28       Impact factor: 11.205

Review 3.  The evolution of tumour phylogenetics: principles and practice.

Authors:  Russell Schwartz; Alejandro A Schäffer
Journal:  Nat Rev Genet       Date:  2017-02-13       Impact factor: 53.242

4.  Monoclonal tumor origin is an underlying misconception of the RESIC approach.

Authors:  Barbara L Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-14       Impact factor: 11.205

5.  Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.

Authors:  Jie Zhang; Angela G Fleischman; Dominik Wodarz; Natalia L Komarova
Journal:  J Theor Biol       Date:  2017-05-10       Impact factor: 2.691

6.  Evolutionary pathways in BRCA1-associated breast tumors.

Authors:  Filipe C Martins; Subhajyoti De; Vanessa Almendro; Mithat Gönen; So Yeon Park; Joanne L Blum; William Herlihy; Gabrielle Ethington; Stuart J Schnitt; Nadine Tung; Judy E Garber; Katharina Fetten; Franziska Michor; Kornelia Polyak
Journal:  Cancer Discov       Date:  2012-04-10       Impact factor: 39.397

7.  Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Authors:  Jaime Acquaviva; Hyun Jung Jun; Julie Lessard; Rolando Ruiz; Haihao Zhu; Melissa Donovan; Steve Woolfenden; Abraham Boskovitz; Ami Raval; Roderick T Bronson; Rolf Pfannl; Charles A Whittaker; David E Housman; Al Charest
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

8.  Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.

Authors:  Tatsuya Ozawa; Markus Riester; Yu-Kang Cheng; Jason T Huse; Massimo Squatrito; Karim Helmy; Nikki Charles; Franziska Michor; Eric C Holland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

9.  Sequencing the AML genome, transcriptome, and epigenome.

Authors:  Elaine R Mardis
Journal:  Semin Hematol       Date:  2014-08-07       Impact factor: 3.851

Review 10.  The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment.

Authors:  Elizabeth A Stoll; Philip J Horner; Robert C Rostomily
Journal:  Aging Cell       Date:  2013-06-28       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.